Abstract
The years 2007 to March 2009 set in motion a severe economic global downturn. The pharmaceutical sector suffered less than other sectors. As global economies started to rise from the depths of the severe recession, some pharmaceutical firms outperformed their peers. This report analyzes the performance of the 22 top (by sales revenue) publicly traded drug firms over six metrics. The report concludes with an assessment of why certain pharmaceutical firms outperformed their peers over the time period: 2009–2014.
Get full access to this article
View all access options for this article.
References
1.
Housel
M
. Playing stocks in turbulent times . Wall Street Journal . 17 January 2015, pp. B7, B9 .
2.
Dobrow
L
. A sunny day in Pharma Land . MM&M . May 2015, pp. 12–18 .
3.
Morgenson
G
. When the stock price hides trouble . New York Times . 13 April 2013, pp. Bu 1, BU 5 .
4.
Trombetta
B
. The 14th annual pharmaceutical industry audit: back on track . Pharmaceut Execut 2015 ; 35 : 30 –37 .
5.
Lewellen
J
. Predicting returns with financial ratios . J Financ Econ 2004 ; 74 : 209 –235 .
6.
Barker
R
. The Barker portfolio: top prospects . Businessweek . 4 April 2005, pp. 82–83 .
7.
Barker
R
. A better way to size up a company . Businessweek . 6 December 2003, pp. 154, 155 .
8.
Morrison
C
Licking
E
. Pharma serious about a change? In Vivo October . 2010, pp. 1–12 .
9.
Condon
T
. Leading indicator . Forbes . 8 March 1999, p. 168 .
10.
Morgenson
G
. Gauging the value of a C.E.O . New York Times . 19 June 2016, pp. Business Section 1, 2 .
11.
Colvin
G
. When victory is worth waiting for . Fortune.com . 1 June 2016, p. 26 .
12.
Benoit
D
. Finance’s hot new metric: ROIC . Wall Street Journal . 4 March 2016, pp. C1, C2 .
13.FactSet Research Systems, Inc., 2015, http://www.factset.com/ .
14.
Goodman
M
. Pharmaceutical industry financial performance . Nat Rev Drug Discovery 2009 ; 8 : 927 –928 .
15.
Trickell
S
. Pharma futures: pathways to value: Pharma in a changing world , Oxford : Meteos Ltd , 2013 .
16.
Hoffman
L
. Valeant wins battle for Salix after higher bid . Wall Street Journal . 17 March 2015, p. B 3 .
17.
Herman
B
. Providers fear insurance mergers could intensify rate pressures . Modern Healthcare 2015 ; 45 : 14 –14 .
18.
Revelle
J
. When picking stocks, bet on pricing power . Fortune 2013 ; 167 : 98 –98 .
19.
Tully
S
. Profit engine on the rails . Fortune 2015 ; 171 : 210 –219 .
20.Cramer J. Ride the four Horsemen of biotech, http://www.thestreet.com/story/12159470/1/jim-cramer-ride-the-four-horsemen-of-biotech (2013, accessed 12 October 2016) .
21.Insights. Seven sure things, CVS Caremark , 2014 .
22.Anonymous, www.businessweek.com (2013, accessed 12 October 2016) .
23.
Strom
S
Bray
C
. Global Grocers’ merger plan points up challenges in the United States . New York Times . 25 June 2015, pp. B1, B4 .
24.
Barr
A
. Google shoots up $25 billion in a day . Wall Street Journal . 18 July 2015, pp. A1, A6 .
25.
Sorkin
A
. The truth hidden by IBM’s buybacks . New York Times . 26 October 2014, pp. B1, B6 .
26.
Coy
P
. P&G stops making sense . Businessweek . 20 April 2015, pp. 25–26 .
27.
Tully
S
. The real key to creating shareholder value . Fortune 1993 ; 159 : 38 –50 .
28.
Thomas
H
. Pharma must launch its way to full health . Wall Street Journal . 17 February 2015, p. C8 .
29.
DataPoints
. $36 Billion . Modern Healthcare 2014 ; 44 : 50 –50 .
30.
Buescher
B
Viguene
P
. How U.S. healthcare companies can thrive amid disruption . Mckinsey.com . June 2014: 1–5 .
31.
Looney
W
. Fifteen years right . Pharmaceut Execut 2016 ; 36 : 3 –3 .